Moderna’s Lofty Aims To Prevent Diseases With Pandemic Potential
Plans Vaccines For 15 'Priority Pathogens'
Executive Summary
The biotech has 15 pathogens in its sights and is also launching mRNA Access that will grant researchers the opportunity to use Moderna's technology platform to develop vaccines for emerging or neglected infectious diseases.
You may also be interested in...
CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work
Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
Moderna Teases M&A Interest As Pandemic Expected To Wind Down
Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.